Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLE-32: Nadofaragene Firadenovec vs Observation in Intermediate-Risk NMIBC
jRCT2063250002Phase 3Recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Apr 2025
- Modality
- Gene Therapies
01
Overview
Phase 3, randomised trial in non-muscle-invasive bladder cancer (NMIBC) comparing Nadofaragene firadenovec with Observation (2 arms). Primary endpoint: Recurrence-free survival (RFS) during treatment period. Started Apr 2025; status: recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2063250002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063250002.